BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Abstract Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combinati...

Descrición completa

Detalles Bibliográficos

Principais autores:	Salar Farokhi Boroujeni, Galaxia Rodriguez, Kristianne Galpin, Edward Yakubovich, Humaira Murshed, Dalia Ibrahim, Sara Asif, Barbara C. Vanderhyden
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-11-01
Series:	Journal of Ovarian Research
Assuntos:	BRCA mutations Ovarian cancer PARP inhibitors Immune checkpoint inhibitors
Acceso en liña:	https://doi.org/10.1186/s13048-023-01313-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!